Shionogi & Co., Ltd. (SGIOY)
- Previous Close
11.21 - Open
11.45 - Bid --
- Ask --
- Day's Range
11.23 - 11.64 - 52 Week Range
10.10 - 13.67 - Volume
55,194 - Avg. Volume
57,812 - Market Cap (intraday)
12.737B - Beta (5Y Monthly) 0.38
- PE Ratio (TTM)
12.62 - EPS (TTM)
0.89 - Earnings Date Jul 29, 2024 - Aug 2, 2024
- Forward Dividend & Yield 0.26 (2.31%)
- Ex-Dividend Date Sep 28, 2023
- 1y Target Est
--
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
www.shionogi.com4,959
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: SGIOY
Performance Overview: SGIOY
Trailing total returns as of 6/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SGIOY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SGIOY
Valuation Measures
Market Cap
12.71B
Enterprise Value
9.13B
Trailing P/E
12.66
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.71
Price/Book (mrq)
1.62
Enterprise Value/Revenue
3.29
Enterprise Value/EBITDA
6.42
Financial Highlights
Profitability and Income Statement
Profit Margin
37.24%
Return on Assets (ttm)
7.02%
Return on Equity (ttm)
13.53%
Revenue (ttm)
435.08B
Net Income Avi to Common (ttm)
162.03B
Diluted EPS (ttm)
0.89
Balance Sheet and Cash Flow
Total Cash (mrq)
358.09B
Total Debt/Equity (mrq)
0.93%
Levered Free Cash Flow (ttm)
--